Bharat Immunologicals & Biologicals (BOM:524663) ROC %: -5.51% (As of Sep. 2023)

What is Bharat Immunologicals & Biologicals ROC %?

Bharat Immunologicals & Biologicals BOM:524663 -0.89% 4 ROC % is -5.51% as of Sep. 2023. GuruFocus rates BOM:524663 with a GF Score™ of 4/100.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Bharat Immunologicals & Biologicals's annualized return on capital (ROC %) for the quarter that ended in Sep. 2023 was -5.51%.

As of today (2026-07-08), Bharat Immunologicals & Biologicals's WACC % is 0.00%. Bharat Immunologicals & Biologicals's ROC % is 0.00% (calculated using TTM income statement data). Bharat Immunologicals & Biologicals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Bharat Immunologicals & Biologicals (BOM:524663) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Bharat Immunologicals & Biologicals's WACC % is 0.00%. Bharat Immunologicals & Biologicals's ROC % is 0.00% (calculated using TTM income statement data). Bharat Immunologicals & Biologicals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Bharat Immunologicals & Biologicals ROC % Related Terms

Bharat Immunologicals & Biologicals ROC % Historical Data

* Premium members only.

The historical data trend for Bharat Immunologicals & Biologicals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bharat Immunologicals & Biologicals ROC % Chart

Bharat Immunologicals & Biologicals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROC %

Get a 7-Day Free Trial

-13.42

-9.28

-15.50

-2.43

-4.89

Bharat Immunologicals & Biologicals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
ROC %	Get a 7-Day Free Trial															-3.12	-3.29	-10.91	-5.51	-5.51

4GF Score

Bharat Immunologicals & Biologicals Corp Ltd BOM:524663

ROC % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Bharat Immunologicals & Biologicals ROC % Calculation

Bharat Immunologicals & Biologicals's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2023 is calculated as:

	ROC % (A: Mar. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Mar. 2022 )	+	Invested Capital (A: Mar. 2023 ))	/ count )
=	-160.074 * ( 1 - 25.28% )	/	( (2457.436	+	2430.059)	/ 2 )
=	-119.6072928	/	2443.7475
=	-4.89 %

where

	Invested Capital		(A: Mar. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2127.286	-	28.201	-	( 46.429	-	max(0, 1012.639	-	654.288	+	46.429	))
=	2457.436

	Invested Capital		(A: Mar. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1886.473	-	38.81	-	( 12.859	-	max(0, 940.424	-	358.028	+	12.859	))
=	2430.059

Bharat Immunologicals & Biologicals's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-188.904 * ( 1 - 26% )	/	( (0	+	2536.976)	/ 1 )
=	-139.78896	/	2536.976
=	-5.51 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1881.313	-	7.785	-	( 89.093	-	max(0, 990.548	-	327.1	+	89.093	))
=	2536.976

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -5.51% mean?

Bharat Immunologicals & Biologicals (BOM:524663) has a ROC % of -5.51% as of Sep. 2023. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Bharat Immunologicals & Biologicals and its competitors.

Is Bharat Immunologicals & Biologicals' ROC % too high?

Bharat Immunologicals & Biologicals' current ROC % is -5.51%. Overall, Bharat Immunologicals & Biologicals has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.

How does Bharat Immunologicals & Biologicals' ROC % compare to VRTX and REGN?

Bharat Immunologicals & Biologicals' ROC % of -5.51% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Biotechnology company?

A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Bharat Immunologicals & Biologicals and its competitors. Bharat Immunologicals & Biologicals's current ROC % is -5.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Bharat Immunologicals & Biologicals stock overvalued right now?

Bharat Immunologicals & Biologicals (BOM:524663) has a current ROC % of -5.51%. The current ROC % is -5.51%. Bharat Immunologicals & Biologicals' overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Bharat Immunologicals & Biologicals (BOM:524663), the current ROC % is -5.51% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bharat Immunologicals & Biologicals Business Description

Industry Healthcare Biotechnology

Comparable Companies BOM:540679 BOM:511509 BOM:526139 BOM:542910 BOM:514336 BOM:539206 BOM:506365 BOM:531207 BOM:532890 BOM:524717 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address Village Chola, BIBCOL, OPV Plant, Bulandshahar, UP, IND, 203203

Website http://www.bibcol.sciencecentral.in

Bharat Immunologicals & Biologicals Corp Ltd is an India-based biotechnology company. It primarily manufactures Oral polio vaccines. In addition, the company also manufactures zinc tablets, diarrhea management kits, and Ready to Use Therapeutic Food (RUTF). It also manufactures nutraceuticals and biological products for the treatment of health deficiencies and disorders. The firm is organized into three segments: Oral Polio Vaccine, Zinc Tablets, and BIB VIT, BIBSANIT. The group principally operates in India and generates the majority of its revenue from sales of Oral polio vaccines.

4GF Score

Get the complete analysis for BOM:524663

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹16.65

Price

View BOM:524663 Analysis

See ROC % data for all stocks →